Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.

Also called NCT03397121

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 482 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03397121
  • EudraCT 2017-002472-30
Other papers using this trial's data
  • Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia The New England journal of medicine, 2020-04-16 DOI, PubMed 32197277

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Netherlands, South Africa, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03397121. Randomized; double masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2019-08-27 (actual). Results posted on 2020-10-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
Acronym
ORION-9
Condition
Heterozygous Familial Hypercholesterolemia
Condition
Elevated Cholesterol
Intervention (Drug)
Inclisiran
Intervention (Drug)
Placebo
Lead sponsor
The Medicines Company (class: industry)

Record details

Record id
cardio:ct-nct03397121
Content hash
c6ab3774e2b3d16df83fdc0977f0469a2b6dd9bacf0d78fe3357703ff4654215